切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2015, Vol. 04 ›› Issue (05) : 232 -235. doi: 10.3877/cma.j.issn.2095-3216.2015.05.003

所属专题: 文献

专家论坛

C1q肾病的诊断及治疗
倪兆慧1,(), 金海姣1, 徐维佳1   
  1. 1. 200127 上海交通大学医学院附属仁济医院肾脏科
  • 出版日期:2015-10-28
  • 通信作者: 倪兆慧
  • 基金资助:
    国家自然科学基金(81370794); 国家科技支撑计划课题(2011BAI10B08)

Diagnosis and treatment of C1q nephropathy

Zhaohui Ni1,(), Haijiao Jin1, Weijia Xu1   

  1. 1. Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
  • Published:2015-10-28
  • Corresponding author: Zhaohui Ni
  • About author:
    Corresponding author: Ni Zhaohui, Email:
引用本文:

倪兆慧, 金海姣, 徐维佳. C1q肾病的诊断及治疗[J]. 中华肾病研究电子杂志, 2015, 04(05): 232-235.

Zhaohui Ni, Haijiao Jin, Weijia Xu. Diagnosis and treatment of C1q nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(05): 232-235.

C1q肾病是一种以系膜增生为主的肾小球疾病,其特点为免疫荧光染色可见系膜区高强度C1q沉积,电镜下可见系膜区电子致密物沉积,根据组织病理学特点主要分为3类,包括微小病变(MCD)、局灶节段性肾小球硬化(FSGS)和免疫介导的增生性肾小球肾炎。C1q肾病的临床表现具有多样性,可表现为肾炎或肾病范围内蛋白尿,伴有或不伴有血尿和肾功能损伤。虽然目前糖皮质激素是治疗C1q肾病的主要方法,但多数研究认为C1q肾病对糖皮质激素治疗反应较差。中西医结合治疗有望提高C1q肾病的疗效。

C1q nephropathy is a glomerular disorder with prominent mesangial proliferation. It is characterized by mesangial dense deposits under electron microscopy and C1q deposits under immunofluorescence microscopy. The histologic pattern of C1q nephropathy can be divided into three kinds: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and immune-mediated proliferative glomerulonephritis. Its clinical presentation is heterogenous, ranging from nephritic to nephrotic proteinuria, with or without hematuria and renal insufficiency. Glucocorticoids remain the mainstay of treatment. Most studies indicated poor response of C1q nephropathy to glucocorticoids. The treatment of integrated Chinese and western medicine for C1q nephropathy is promising.

1
Malleshappa P, Vankalakunti M. Diverse clinical and histology presentation in C1q nephropathy [J]. Nephrourol Mon, 2013, 5(3): 787-791.
2
Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome [J]. Am J Kidney Dis, 1985, 6(2): 103-110.
3
Markowitz GS, Schwimmer JA, Stokes MB, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis [J]. Kidney Int, 2003, 64(4): 1232-1240.
4
Meyrier A, Gerald BA. Minimal change variants: mesangial proliferation; IgM nephropathy[DB/OL]. UpToDate, 2014,

URL    
5
Kersnik Levart T, Kenda RB, Avgustin Cavic M, et al. C1Q nephropathy in children [J]. Pediatr Nephrol, 2005, 20(12): 1756-1761.
6
van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. Both IgG- and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells [J]. J Am Soc Nephrol, 1996, 7(4): 573-581.
7
Thomas DB. Focal segmental glomerulosclerosis: a morphologic diagnosis in evolution [J]. Arch Pathol Lab Med, 2009, 133(2): 217-223.
8
Isaac J, Shihab FS. De novo C1q nephropathy in the renal allograft of a kidney pancreas transplant recipient: BK virus-induced nephropathy [J]? Nephron, 2002, 92(2): 431-436.
9
Mii A, Shimizu A, Masuda Y, et al. Current status and issues of C1q nephropathy [J]. Clin Exp Nephrol, 2009, 13(4): 263-274.
10
Vizjak A, Ferluga D, Rozic M, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy [J]. J Am Soc Nephrol, 2008, 19(11): 2237-2244.
11
Srivastava T, Chadha V, Taboada EM, et al. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis [J]. Pediatr Nephrol, 2000, 14(10-11): 976-979.
12
Emanicipator SN. Benign essential hematuria, IgA nephropathy, and Alport syndrome [J]. Renal Biopsy Interpretation, 1996, 10(2): 147-180.
13
Srivastava T, Chadha V. C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis [J]. Clin Exp Nephrol, 2009, 13(4): 263-274.
14
Kersnik Levart T, Kenda RB, Avgustin Cavic M, et al. C1Q nephropathy in children [J]. Pediatr Nephrol, 2005, 20(12): 1756-1761.
15
Hisano S, Fukuma Y, Segawa Y, et al. Clinicopathologic correlation and outcome of C1q nephropathy [J]. Clin J Am Soc Nephrol, 2008, 3(6): 1637-1643.
16
赵三龙,黄松明,朱春华,等. 儿童C1q肾病的临床病理特点及治疗[J].中华肾脏病杂志,2011,12(27): 877-883.
17
Sinha A, Nast CC, Hristea I, et al. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy [J]. Clin Exp Nephrol, 2011, 15(1): 164-170.
[1] 王宏宇. 固定与活动平台假体在全膝关节置换术中的应用价值[J]. 中华关节外科杂志(电子版), 2023, 17(06): 871-876.
[2] 李善武, 叶永杰, 王兵, 王子呓, 银毅, 孙官军, 张大刚. 胫骨高位截骨与单髁置换的早期疗效比较[J]. 中华关节外科杂志(电子版), 2023, 17(06): 882-888.
[3] 张伟. 牙及牙槽外科:舒适治疗的先锋[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 386-388.
[4] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[7] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[8] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[9] 许丁伟, 马江云, 李新成, 黄洁. Alagille综合征疑诊为先天性胆道闭锁一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 681-687.
[10] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[11] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[12] 邱朋, 邓正栋, 王剑明. 肝内胆管结石微创治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 591-596.
[13] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[14] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要